STOCKWATCH
·
 Medicinal Chemicals and Botanical Products
Quarterly ResultMay 11, 2026, 07:36 AM

Cronos Q1 Net Revenue +40% to $45.2M; Net Income +103%; $50M Buyback

AI Summary

Cronos Group Inc. reported strong first-quarter 2026 financial results, with net revenue increasing 40% year-over-year to $45.2 million and net income surging 103% to $15.7 million. The company also announced a new share repurchase program, authorizing up to $50 million in buybacks to succeed the expiring program. Additionally, Cronos extended the long stop date for its acquisition of CanAdelaar B.V. to September 9, 2026, to allow more time for regulatory clearances.

Key Highlights

  • Net revenue increased 40% year-over-year to $45.2 million in Q1 2026.
  • Net income rose 103% year-over-year to $15.7 million in Q1 2026.
  • Adjusted EBITDA improved 122% year-over-year to $5.1 million.
  • Board authorized a new $50 million share repurchase program, effective May 14, 2026.
  • Extended CanAdelaar B.V. acquisition closing date to September 9, 2026.
  • Cronos Israel's PEACE NATURALS® brand achieved 53% YoY net revenue growth.
  • Spinach® brand reached #1 market share in Canadian vapes (9.8%) and edibles (20.8%).
  • Cash and cash equivalents totaled $821.9 million as of March 31, 2026.
CRON
Medicinal Chemicals and Botanical Products
Cronos Group Inc.

Price Impact